BioVision Introduces EZSolution™ "ready-to-use" Inhibitors
| BioVision recently introduced a number of EZSolution™ Inhibitors that should be very useful for researchers studying key Signal Transduction Pathways such as GSK-3 signaling, MAP Kinase signaling, PI3-K/Akt/mTOR signaling, etc. |
FOR IMMEDIATE RELEASE
PRLog (Press Release) – Oct 25, 2010 – Drugs that function as enzyme inhibitors constitute a major portion of the therapeutic agents that are in clinical use today, underscoring the increasing demand for enzyme inhibitors as useful tools in drug discovery research. To meet the researcher's demand, BioVision recently introduced a number of EZSolution™ Inhibitors in a convenient "ready-to-use" form. These inhibitors should be very useful for researchers studying key Signal Transduction Pathways such as GSK-3 signaling, MAP Kinase signaling, PI3-K/Akt/mTOR signaling, etc.
About BioVision:
BioVision, Inc. is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, and more.
